PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025

Company Overview - PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care in urology by developing transformative solutions [3] - The company manufactures the AQUABEAM and HYDROS™ Robotic Systems, with the HYDROS system being the only AI-powered technology delivering Aquablation therapy [3] - Aquablation therapy is designed to provide effective, safe, and durable outcomes for men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), independent of prostate size and surgeon experience [3] Financial Reporting - The company will report its financial results for the third quarter of 2025 after market close on November 4, 2025 [1] - A conference call will be hosted by the company's management at 4:30 p.m. Eastern Time on the same day [1] Clinical Evidence - PROCEPT BioRobotics has developed a significant body of clinical evidence with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy [3] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [3]